Search Results - "de Boer, Fransien"

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme by van der Helm, Lieke H., Alhan, Canan, Wijermans, Pierre W., van Marwijk Kooy, Marinus, Schaafsma, Ron, Biemond, Bart J., Beeker, Aart, Hoogendoorn, Mels, van Rees, Bastiaan P., de Weerdt, Okke, Wegman, Jurgen, Libourel, Ward J., Luykx‐de Bakker, Sylvia A., Minnema, Monique C., Brouwer, Rolf E., Croon‐de Boer, Fransien, Eefting, Matthijs, Jie, Kon‐Siong G., van de Loosdrecht, Arjan A., Koedam, Jan, Veeger, Nic J. G. M, Vellenga, Edo, Huls, Gerwin

“…Summary The efficacy of azacitidine in the treatment of high‐risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid…”
Get full text

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia by Leeksma, Alexander C., Taylor, Justin, Wu, Bian, Gardner, Jeffrey R., He, Jie, Nahas, Michelle, Gonen, Mithat, Alemayehu, Wendimagegn G., te Raa, Doreen, Walther, Tatjana, Hüllein, Jennifer, Dietrich, Sascha, Claus, Rainer, de Boer, Fransien, de Heer, Koen, Dubois, Julie, Dampmann, Maria, Dürig, Jan, van Oers, Marinus H. J., Geisler, Christian H., Eldering, Eric, Levine, Ross L., Miller, Vincent, Mughal, Tariq, Lamanna, Nicole, Frattini, Mark G., Heaney, Mark L., Zelenetz, Andrew, Zenz, Thorsten, Abdel-Wahab, Omar, Kater, Arnon P.

“…Genomic analyses of chronic lymphocytic leukemia (CLL) identified somatic mutations and associations of clonal diversity with adverse outcomes. Clonal…”
Get full text

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment by de Weerdt, Iris, Hofland, Tom, de Boer, Renate, Dobber, Johan A., Dubois, Julie, van Nieuwenhuize, Denise, Mobasher, Mehrdad, de Boer, Fransien, Hoogendoorn, Mels, Velders, Gerjo A., van der Klift, Marjolein, Remmerswaal, Ester B.M., Bemelman, Frederike J., Niemann, Carsten U., Kersting, Sabina, Levin, Mark-David, Eldering, Eric, Tonino, Sanne H., Kater, Arnon P.

“…Morbidity and mortality due to immunosuppression remain among the foremost clinical challenges in chronic lymphocytic leukemia (CLL). Although…”
Get full text

P1523: IMMUNOGENICITY OF THE 13‐VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23‐VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA by Haggenburg, Sabine, Garrido, Hannah Garcia, Kant, Iris, Straaten, Hanneke, Boer, Fransien De, Kersting, Sabina, Issa, Djamila, Raa, Doreen Te, Visser, Hein, Kater, Arnon, Goorhuis, Abraham, Heer, Koen De

Get full text

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia by Haggenburg, Sabine, Garcia Garrido, Hannah M, Kant, Iris M J, Van der Straaten, Hanneke M, De Boer, Fransien, Kersting, Sabina, Issa, Djamila, Te Raa, Doreen, Visser, Hein P J, Kater, Arnon P, Goorhuis, Abraham, De Heer, Koen

“…Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults…”
Get full text

P629: THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT‐ACALL TRIAL by Niemann, Carsten, Levin, Mark‐David, Österborg, Anders, Lundin, Jeanette, Kättström, Magdalena, Vollerup, Jeanette, Da Cunha‐Bang, Caspar, Foraux, Michael, Brieghel, Christian, Boer, Fransien, Enggaard, Lisbeth, Bjorn Poulsen, Christian, Reekie, Joanne, Agius, Rudi

Get full text

P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB‐VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL by Kersting, Sabina, Levin, Mark‐David, Dubois, Julie, Norden, Yvette, Dobber, Johan, Jauw, Yvonne, Kevie‐Kersemaekers, Anne‐Marie, Mellink, Clemens, Da Cunha‐Bang, Caspar, Van Desr Burg, Leonie, Te Raa, Doreen, Boer, Fransien, Droogendijk, Jolanda, Idink, Cecile, De Heer, Koen, Nijziel, Marten, Tick, Lidwine, Ludwig, Inge, Silbermann, Mathijs, Beeker, Aart, Bellido, Mar, Evers, Ludo, Zwezerijnen, Gerben, Zijlstra, Josée, Kap, Marcel, Niemann, Carsten, Kater, Arnon

Get full text

P877: IXAZOMIB DARATUMUMAB AND LOW‐DOSE DEXAMETHASONE IN INTERMEDIATE‐FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY by Groen, Kaz, Stege, Claudia, Nasserinejad, Kazem, Heer, Koen, Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka‐Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie‐Christiane, Donk, Niels W.C.J., Timmers, Gert‐Jan, Boer, Fransien, Tick, Lidwine W., Spek, Ellen, Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., Levin, Mark‐David, Ypma, Paula F., Zweegman, Sonja

Get full text

Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia by Tonino, Sanne H., Mulkens, Chantal E., van Laar, Jacoline, Derks, Ingrid A. M., Suo, Guangli, Croon-de Boer, Fransien, van Oers, Marinus H. J., Eldering, Eric, Wang, Jean Y., Kater, Arnon P.

“…In chronic lymphocytic leukemia (CLL), strategies to overcome drug resistance due to p53 dysfunction are highly needed. Platinum-based compounds such as…”
Get full text

Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients with Chronic Lymphocytic Leukaemia by Haggenburg, Sabine, Garcia Garrido, Hannah, Kant, Iris, De Boer, Fransien, Kersting, Sabina, Raa, Doreen te, Issa, Djamila E., Otten, Henny G., Visser, Hein P.J., Kater, Arnon P., Goorhuis, Abraham, de Heer, Koen

Get full text

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial by Broome, Catherine M, McDonald, Vickie, Miyakawa, Yoshitaka, Carpenedo, Monica, Kuter, David J, Al-Samkari, Hanny, Bussel, James B, Godar, Marie, Ayguasanosa, Jaume, De Beuf, Kristof, Rodeghiero, Francesco, Michel, Marc, Newland, Adrian, Fillitz, Michael, Knoebl, Paul, Meers, Stef, Amine, Ismail Mohamad, Gumulec, Jaromir, Hlusi, Antonin, Mayer, Jiri, Quittet, Philippe, Viallard, Jean-Francois, Betaneli, Magdana, Datikashvili-David, Irine, Iosava, Genadi, Makhaldiani, Levan, Rejto, Laszlo, Sharashenidze, Nino, Groepper, Stefanie, Röth, Alexander, Hamed, Aryan, Illes, Arpad, Artoni, Andrea, Bocchia, Monica, Gamberi, Barbara, Borchiellini, Alessandra, Oliva, Esther Natalie, Patriarca, Andrea, Tomassetti, Simona, Ando, Kiyoshi, Handa, Hiroshi, Katsutani, Shinya, Nishiwaki, Kaichi, Ito, Shoko, Ito, Tomoki, de Boer, Fransien, Jansen, A.J. Gerard, Ciepluch, Hanna, Fornagiel, Szymon, Grosicki, Sebastian, Soroka-Wojtaszko, Maria, Trelinski, Jacek, Bakirov, Bulat, Borisenkova, Elena, Volodicheva, Elena, Shatokhin, Yuri, Proydakov, Andrey, Alonso, Maria Aranzazu, Mingot-Castellano, María Eva, Sanchez-Gonzalez, Blanca, Valcarcel Ferreiras, David, Ayli, Meltem, Hacibekiroglu, Tuba, Demir, Ahmet Muzaffer, Nalçaci, Meliha, Sonmez, Mehmet, Tombak, Anil, Toprak, Selami Kocak, Turgut, Burhan, Vural, Filiz, Yagci, Munci, Altuntas, Fevzi, Turgut, Mehmet, Kaya, Emin, Romanyuk, Nataliya, Kazmi, Syed Rashid Saeed, Broome, Catherine, Cataland, Spero, Doshi, Ketan, Lentz, Steven R., Boxer, Michael, Rosenberg, Richard

“…Summary Background Primary immune thrombocytopenia is an autoimmune disorder mediated partly by platelet autoantibodies, resulting in thrombocytopenia,…”
Get full text

Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational study by Ruchlemer, Rosa, Ben‐Ami, Ronen, Bar‐Meir, Maskit, Brown, Jennifer R., Malphettes, Marion, Mous, Rogier, Tonino, Sanne H., Soussain, Carole, Barzic, Noelie, Messina, Julia A., Jain, Preetesh, Cohen, Regev, Hill, Brian, Mulligan, Stephen P., Nijland, Marcel, Herishanu, Yair, Benjamini, Ohad, Tadmor, Tamar, Okamoto, Koh, Arthurs, Benjamin, Gottesman, Batsheva, Kater, Arnon P., Talha, Munir, Eichhorst, Barbara, Korem, Maya, Bogot, Naama, De Boer, Fransien, Rowe, Jacob M., Lachish, Tamar

“…Summary Background Invasive fungal diseases (IFD) are life‐threatening infections most commonly diagnosed in acute leukaemia patients with prolonged…”
Get full text

Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial by Levin, Mark-David, Kersting, Sabina, Dubois, Julie M.N., Norden, Yvette, Dobber, Johan A, Jauw, Yvonne W.S., Kevie-Kersemaekers, Anne-Marie van der, Mellink, Clemens, Heer, Koen de, Burg, Leonie van der, Raa, Doreen Te, Boer, Fransien de, Droogendijk, Jolanda, Idink, Cecile, Nijziel, Marten R., Tick, Lidwine W., Ludwig, Inge, Silbermann, Matthijs, Beeker, Aart, Bellido, Mar, Evers, Ludo M., Zwezerijnen, Gerben JC, Niemann, Carsten U, Kater, Arnon P.

Get full text

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL by van der Straten, Lina, Stege, Claudia A. M., Kersting, Sabina, Nasserinejad, Kazem, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F. M., Visser, Hein P. J., Houtenbos, Ilse, Idink, Cecile A. M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C. T., Veelken, J. Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Westerweel, Peter E., Langerak, Anton W., Kater, Arnon P., Levin, Mark-David, Beckers, M. M. J., Bekker, A., Bellido, M., de Boer, F., Broers, R., Chamuleau, M., Croockewit, A. J., Dompeling, E. C., Eefting, M., van Gelder, M., Hoogendoorn, M., Houtenbos, I., Doorduijn, J. K., Droogendijk, J., van der Griend, R., de Heer, K., Henkens, C. M. A., Idink, C. A. M., Issa, D. E., van Kampen, R., Kater, A. P., Kersting, S., van der Klift, M., Laterveer, L., Levenga, H., Levin, M-D., Mous, R., Nijland, M., Nijziel, M., van Norden, Y., Posthuma, E. F. M., te Raa, G. D., Raymakers, R. A. P., Regelink, J. C., Sandberg, Y., Schaafsma, M. R., Silbermann, M. H., van der Spek, A. C., van der Straaten, H. M., Tanis, B., Terpstra, W. E., Tick, L. W., Tonino, S. H., Veelken, J. H., Velders, G. A., Vlasveld, L., Visser, H. P. J., Vos, J. M. I., Wittebol, S., van Zaanen, H. C. T.

“…•Geriatric assessments can aid in identifying patients with less physical resilience who are at increased risk of grade ≥3 adverse events.•Fixed-duration Ven-O…”
Get full text

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study by Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, Van Kampen, Roel J.W., Leijs, Maria B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka Lung, Ludwig, Inge, Issa, Djamila, Velders, Gerjo A., Vekemans, Marie-Christiane, van de Donk, Niels W.C.J., Timmers, Gert-Jan, Sonneveld, Pieter, Seefat, Maarten R., Croon-de Boer, Fransien, Tick, Lidwine W., van der Spek, Ellen, De Waal, Esther G.M., Sohne, Maaike, Ypma, Paula F, Nijhof, Inger S., Klein, Saskia K., Levin, Mark-David, Zweegman, Sonja

“…Introduction Non-transplant eligible newly diagnosed multiple myeloma (NTE-NDMM) patients have a heterogeneous clinical outcome, which can be partly explained…”
Get full text

Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry by Ekels, Afke, van de Poll-Franse, Lonneke V, Issa, Djamila E, Hoogendoorn, Mels, Nijziel, Marten R, Koster, Adrianus, de Jong, Cornelis N, Achouiti, Ahmed, Thielen, Noortje, Tick, Lidwine W, Te Boome, Liane C J, Bohmer, Lara H, Tiren-Verbeet, Nicolette L, Veldhuis, Gerrit J, de Boer, Fransien, van der Klift, Marjolein, Posthuma, Eduardus F M, Oerlemans, Simone

“…With the increasing prevalence of comorbidity in an ageing population, it is crucial to better understand the impact of comorbidity on health-related quality…”
Get full text

First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment by de Weerdt, Iris, Hofland, Tom, Dobber, Johan, Dubois, Julie, Eldering, Eric, Mobasher, Mehrdad, Croon-de Boer, Fransien, Hoogendoorn, Mels, Velders, Gerjo A., van der Klift, Marjolein, Levin, Mark-David, Kersting, Sabina, Tonino, Sanne, Kater, Arnon P.

“…Introduction Chronic lymphocytic leukemia (CLL) is characterized by a profound immune suppression. In addition, CLL cells evade immune destruction by…”
Get full text

Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study by Saberi Hosnijeh, Fatemeh, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, te Raa, G. Doreen, Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., Levin, Mark-David

“…•The prognostic ability of IGHV mutational status and sex was validated in this cohort.•The markers sCD23, SPINT1, and LY9 have possible prognostic ability for…”
Get full text

Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial by Kater, Arnon P., Van Oers, Marinus H.J. H.J., Norden, Yvette, Liu, Roberto D., Schipperus, Martin R., Chamuleau, Martine, Nijland, Marcel, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, Croon-de Boer, Fransien, Wittebol, Shulamit, Kerst, Martijn, Marijt, Willem, Posthuma, Ward, Raymakers, Reinier, Schaafsma, Ron, Dobber, Johan, Kersting, Sabina, Levin, Mark-David

“…Introduction. Since publication of the pivotal CLL011 phase 3 trial, combination of chlorambucil and anti-CD20 MAb has become the standard first-line CLL…”
Get full text

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial by Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka-Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie-Christiane, Timmers, Gert-Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark-David, Ypma, Paula F., Zweegman, Sonja

Get full text